Asaris

Method of action: Antiallergic, Anti-Asthmatic, Anti-Inflammatory, Beta-Adrenomimetic, Bronchodilator, Drugs For Obstructive Airway Diseases, Glucocorticoid

Treatment option: Asthma

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Asaris

Property	Description
Active Ingredients	Fluticasone Propionate, Salmeterol
Form	Inhalation Powder or Metered-Dose Inhaler
Pharmacological Class	Respiratory Inhalant Combination
Common Purpose	Long-term control and maintenance therapy
Origin	Synthetic Compounds

What Type of Medicine is Asaris?

Asaris is a fixed-dose combination product for respiratory management administered exclusively via inhalation. It is formally classified under the Anatomical Therapeutic Chemical (ATC) code system as R03AK06, designated for Adrenergics in combination with corticosteroids. The drug contains two distinct active components: the Inhaled Corticosteroid (ICS), Fluticasone Propionate, and the Long-Acting beta2-Adrenoceptor Agonist (LABA), Salmeterol.

This FDC is clinically recognized for its synergistic approach, integrating anti-inflammatory and bronchodilating effects into a single treatment. The combination ensures that the two complementary actions—inflammation control and bronchodilation—are delivered simultaneously in one pharmaceutical unit, a standard method for achieving long-term stability in airway function.

Composition, Origin, and Delivery Form

The active agents in Asaris, Fluticasone Propionate, a glucocorticoid, and Salmeterol, an adrenergic agonist, are both complex synthetic compounds. Asaris is formulated into specialized dosage form(s) for pulmonary delivery, typically available as an Inhalation Powder or a pressurized Metered-Dose Inhaler (Aerosol). The intended route of administration is inhalation, which ensures the active ingredients are carried directly to the airways, often using an inert base/vehicle such as lactose or a hydrofluoroalkane (HFA) propellant.

General Purpose: A Controller for Long-Term Management

The general purpose of Asaris is to serve as a controller inhaler used for routine, scheduled maintenance therapy in chronic airway conditions. Its dual mechanism works collectively to stabilize breathing function and prevent the symptoms of recurrent airway constriction. This design aims to manage the chronic nature of air flow blockage and airway inflammation over the long term, offering sustained protection where a single agent may be insufficient.

Regulatory References

NIH MedlinePlus Drug Information on Fluticasone and Salmeterol

What side effects are possible with Asaris?

Possible Side Effects and Safety Information

Official regulatory documents classify the potential side effects of the fixed-dose combination of fluticasone propionate and salmeterol (Asaris) based on frequency and the body system affected. The safety profile is structured to identify expected reactions, clinically significant warnings, and population-specific considerations.

Adverse Reaction Categories

Side effects are categorized by frequency observed in clinical trials, with Headache and Nasopharyngitis being classified as Very Common. Reactions listed as Common include local effects such as Oral Candidiasis (thrush), Pharyngitis, Dysphonia (hoarseness), and Throat Irritation, as well as systemic effects like Bronchitis and Musculoskeletal pain. System-organ-class groupings also note potential effects on the Nervous System (e.g., Tremor) and Cardiac System (e.g., Palpitations, Tachycardia).

Serious Adverse Reactions and Safety Constraints

Regulatory warnings highlight the potential for Paradoxical Bronchospasm, an acute, severe reaction requiring immediate attention. The drug also carries the risk of Immediate Hypersensitivity Reactions (such as Angioedema or Anaphylaxis). Due to the corticosteroid component, there is a documented potential for systemic effects, including Adrenal Suppression and increased risk of Pneumonia in patients with Chronic Obstructive Pulmonary Disease (COPD).

Long-Term Exposure is officially associated with the potential for decreased Bone Mineral Density (BMD) and the formation of Glaucoma or Cataracts. Safety constraints also include the need for growth monitoring in pediatric patients and high-level caution regarding use in individuals with pre-existing Cardiovascular disorders or when co-administered with certain Strong Cytochrome P450 3A4 Inhibitors.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Asaris (Fluticasone Propionate and Salmeterol) classifies overdose manifestations based on the effects of its two active components.

Overdose manifestations stemming from the Salmeterol component are consistent with excessive beta-adrenergic stimulation and include documented clinical signs such as tachycardia (fast heart rate), tremor, and headache. Severe outcomes can involve cardiac arrhythmias and metabolic disturbances like hypokalemia and hyperglycemia.

Overuse of the Fluticasone Propionate component, particularly chronic exposure to higher-than-recommended dosages, is associated with risks of hypercorticism and adrenal suppression. Acute inhalation of excessive doses may result in a temporary, reversible suppression of adrenal function, which requires subsequent monitoring of the adrenal reserve.

Immediate medical attention is required if signs of a severe overdose occur, explicitly including if an individual has collapsed, had a seizure, has trouble breathing, or cannot be awakened. The regulatory guidance describes cardioselective beta-blocking agents as the preferred antidote for the Salmeterol component overdosage, alongside supportive measures like potassium replacement for documented hypokalemia.

Therapeutic Uses of Asaris

Asaris (fluticasone/salmeterol) is generally considered relevant as a maintenance treatment for long-term control of chronic airway diseases in adults and children. It is primarily prescribed for chronic conditions such as moderate to severe persistent asthma and the daily management of Chronic Obstructive Pulmonary Disease (COPD), including chronic bronchitis and emphysema.

What Asaris Treats: Main Uses and Benefits

Asaris is applied for the long-term, routine management of conditions involving episodic or fluctuating manifestations, relevant in clinical settings where patients require additional symptomatic support beyond single-agent treatments. It is used to provide supportive relief from symptoms related to heightened physiological activity in the airways, including recurrent wheezing, shortness of breath (dyspnea), and persistent chest tightness.

This daily therapy assists with maintaining functional stability when symptoms are more noticeable. It is commonly used during phases where symptoms create noticeable physiological strain and may assist in managing the risk and overall burden of respiratory exacerbations (flare-ups).

“Maintaining better baseline stability in the airways may contribute to easing the overall reliance on short-acting rescue inhalers.”

Quick Fact: Symptomatic Support for Chronic Conditions
Asaris is commonly used for symptoms that create noticeable physiological strain, applied within contexts involving chronic, recurrent manifestations.

The long-term nature of this therapy may be part of a strategy to support management of the risk of acute breathing crises and contributes to improved day-to-day comfort.

Regulatory References

NIH MedlinePlus overview

Eligibility and Restrictions for Use

Eligibility Profile: Populations Who Can and Cannot Use Asaris

Official regulatory documents define the eligibility for Asaris based on contraindications, age restrictions, and specific patient conditions.

Eligibility Scope	Official Regulatory Status	Practical Implication
Contraindicated Populations	Known hypersensitivity to the active substance (Asaris) or any component of the formulation.	Must not use the medicine.
Pediatric Patients	Use is not recommended or not established in children under a specified minimum age (e.g., typically under 6 years or 2 years), as defined in the specific label.	Use is generally restricted to the labeled patient population (e.g., patients aged 6 years and older).
Organ Impairment	Use is restricted or may be not recommended in patients with severe Hepatic Impairment or severe Renal Impairment unless permitted by label.	Requires careful medical review; use is avoided in the most severe cases.
Pregnancy/Lactation	Use is typically contraindicated or not recommended during pregnancy and breastfeeding.	Use is formally prohibited or discouraged due to documented potential risk to the fetus or infant.

The official eligibility criteria mandate that Asaris must not be administered to patients who have a confirmed allergy to the drug. Furthermore, use is formally restricted by age, excluding the youngest pediatric patients for whom safety and efficacy data may not be established. The official labeling also defines specific physiological states (such as severe organ dysfunction) or co-existing clinical conditions that formally restrict or prohibit the use of Asaris, ensuring that the medicine is reserved for the population where its regulatory profile is considered safe and appropriate.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

This section summarizes the officially documented drug-drug and drug-product interaction profile for Asaris (Fluticasone Propionate/Salmeterol), based on regulatory prescribing information.

Formal Restrictions and Warnings

Interaction Type	Interacting Substance/Class	Regulatory Advisory
Contraindicated Combination	Other Long-Acting beta2-Agonists (LABAs)	Co-administration is prohibited due to risk of excessive adrenergic stimulation.
Pharmacokinetic (PK) Interaction	Strong CYP3A4 Inhibitors (e.g., Ritonavir, Ketoconazole)	Not recommended; significantly increases systemic exposure to both active ingredients.

Pharmacodynamic Interactions

Co-administration with certain medicinal products requires caution due to potential additive effects primarily related to the Salmeterol component:

Monoamine Oxidase Inhibitors (MAOIs) and Tricyclic Antidepressants (TCAs): These medicines may potentiate the vascular effects of Salmeterol.
Beta-Adrenergic Blocking Agents (Beta-Blockers): These agents may block the bronchodilatory effects of Salmeterol.
Non-Potassium-Sparing Diuretics: Concurrent use may worsen the risk of hypokalemia or ECG changes associated with beta2-agonists.

Mechanism of Action

How Asaris Works

Targeting Key Receptors and Enzymes

Asaris exerts its primary action by engaging specific biological targets, such as defined receptors or enzyme systems, within the body. This interaction initiates or blocks molecular steps, thus modulating activity within systems where specific transmitters or mediators dominate.

Modifying Signal Transduction Cascades

The drug operates within well-characterized molecular cascades by altering signaling dynamics. By modifying early molecular steps, Asaris influences and dampens excessive signaling sequences, which regulates processes driven by distinct and often overactive signaling patterns.

Adjusting Dysregulated Physiological Responses

Ultimately, Asaris's targeted pathway adjustment engages mechanisms that regulate overactive or dysregulated physiological processes. This mechanism influences and adjusts overall physiological responses by limiting the impact of excessive mediator activity, resulting in physiological adjustments that characterize the drug's effect profile.

Dosage and Administration Information

How to Use Asaris: Administration Guidelines

Asaris (fluticasone propionate/salmeterol) is designed exclusively for oral inhalation as a long-term maintenance treatment and is not approved for immediate relief of sudden breathing problems. The medication is available as an Inhalation Powder (DPI) and a pressurized Metered-Dose Inhaler (MDI). The specific device and strength used determine the final dosing regimen.

Standard Labeled Dosing and Schedule

Administration for all approved indications is based on a fixed twice-daily schedule, with doses taken approximately 12 hours apart in the morning and evening. The prescribed dosage is determined by the specific condition being managed:

Adult Asthma (ge 12 years): Dosing typically starts with 1 inhalation of the prescribed strength (e.g., 100/50 mcg, 250/50 mcg, or 500/50 mcg DPI) twice daily. Dosage should be titrated to the lowest effective dose needed to maintain control.
Adult COPD: The standard approved DPI dosage is 1 inhalation of 250/50 mcg twice daily.

For pediatric asthma patients (4 to 11 years), the typical dosage is 1 inhalation of the 100/50 mcg DPI twice daily. No dose adjustment is generally required for older adults or individuals with renal impairment.

Essential Procedural Steps

Proper use of Asaris requires specific procedural steps to ensure effective administration and minimize local effects. The MDI formulation must be primed (sprayed into the air) before initial use or after a period of non-use. Critically, the mouth must be rinsed with water immediately after each dose, with the water then spat out and not swallowed. If a dose is missed, the patient should continue with the next scheduled dose; do not take an extra dose to compensate.

Recent Clinical Evidence

The evidence base for the fluticasone propionate/salmeterol combination is primarily derived from Randomized Controlled Trials (RCTs) and systematic reviews, focusing on outcomes in persistent asthma and moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD).

Evidence Base for Persistent Asthma

The combination was evaluated in people with persistent asthma whose symptoms were observed to be fluctuating or unstable while participating in research, after receiving an inhaled corticosteroid (ICS) alone. Studies monitored the frequency and severity of asthma flare-ups (exacerbations) and changes in objective measures of breathing function, such as FEV1 (Forced Expiratory Volume in 1 second).

Studies report patterns where the group receiving the combination was associated with differences in the frequency of exacerbations compared to other tested groups.
Research highlights that the measured changes in lung function were observed to vary between the combination groups and the monotherapy groups.

Evidence Base for Chronic Obstructive Pulmonary Disease (COPD)

For individuals with COPD, the combination was evaluated in major, long-term RCTs, with some observation periods extending up to three years. These studies explored two main axes: the rate of episodic changes (COPD exacerbations) and functional outcomes ( FEV1 and patient-reported health status scores).

In these studies, data show patterns related to the frequency of exacerbations in the combination group compared to placebo or the single bronchodilator component.
Trials monitored and described measured changes in lung function ( FEV1) observed during the study period across the groups.

Research Gaps and Uncertainties

The evidence landscape is derived from Randomized Controlled Trials, although certain limitations exist. Research provides context but not individual predictions. The conclusive long-term effect of the combination on all-cause mortality in COPD is not fully established by definitive statistical certainty from the single primary RCT, though a reduction in reported survival was observed. Follow-up durations were limited in many initial asthma studies, providing less information for outcomes extending beyond one year.

Frequently Asked Questions (FAQ)

Common questions about Asaris (FAQ)

Q: Can I use a spacer device with Asaris?

Regulatory documents indicate that the Dry Powder Inhaler (DPI) formulation of this medication should not be used with a spacer or volume holding chamber. However, the official labeling for the Metered-Dose Inhaler (MDI) device is the only source that specifies whether or not a spacer device is compatible.

Q: Why is Asaris not recommended for children under 4 years old?

Official prescribing information for this drug combination often restricts use to specific age groups. This non-recommendation for younger children is generally because safety and efficacy data have not been established or are considered insufficient for that population, as indicated in regulatory documents.

Q: What happens if I swallow the water when I rinse my mouth after a dose?

Official instructions recommend rinsing your mouth and spitting the water out after each dose to help minimize the risk of local side effects, such as oral thrush. Swallowing the rinse water may increase the amount of medication absorbed systemically, which could slightly increase the potential for systemic effects, such as those related to the adrenal glands.

Q: How should I clean the Asaris inhaler device?

The official instructions for use advise against washing the inhaler or attempting to take the device apart. The instructions typically describe cleaning the device by gently wiping the mouthpiece with a clean, dry tissue.

Q: What is the expiration date of the unopened foil pouch?

The expiration date for the unopened foil pouch is determined by the manufacturer and is printed directly on the product's packaging, usually showing a specific month and year. This date represents the point up to which the manufacturer guarantees the product is fully potent and stable.

Q: Can I stop taking Asaris when my asthma symptoms improve?

According to official product information, this maintenance therapy should not be stopped abruptly. Sudden cessation, especially for asthma, may be associated with a worsening of symptoms (an exacerbation). Any changes to therapy, including stopping treatment, should be discussed with a healthcare professional.

Q: Where can I buy Asaris without a prescription?

Regulatory authorities classify this medication as a Prescription-Only Medicine (POM) in most regulated markets. This indicates that it requires a prescription from a licensed healthcare professional for legal purchase and use.

Q: How long does it take for Asaris to start working?

Official information on the drug's pharmacodynamics indicates that the bronchodilator component begins to act quickly, with measurable concentrations reached within minutes of inhalation. The steroid component, however, works over time to control inflammation, and the full maintenance benefits are realized through long-term, routine use.

How should Asaris be stored and disposed of?

Official Storage and Disposal Instructions

The storage and disposal of Asaris (fluticasone/salmeterol) are subject to official regulatory requirements to ensure product integrity and safety.

Requirement Area	Official Rule
Temperature	Store at Controlled Room Temperature, 20 to 25 C.
Protection	Keep away from direct heat, sunlight, and moisture. Do not freeze the Metered-Dose Inhaler (MDI) canister.
Stability Limit	The Inhalation Powder device must be discarded mathbf1 month (30 days) after the foil pouch is opened, or when the dose counter reads “0.”
Handling	Do not wash the inhaler device, puncture the pressurized MDI canister, or expose it to fire, even if empty.
Safety	The medication must be kept out of the sight and reach of children.
Disposal	Dispose of unused or expired product according to local regulations or instructions from a healthcare professional.